Acute Kidney Injury Market Size (7MM) was ~USD 6,230 million in 2022 and is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Discover Key Insights into the Acute Kidney Injury Market with DelveInsight's In-Depth Report @ Acute Kidney Injury Market Size- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Kidney Injury Market Report
• 05 November 2025, Genentech Inc. announced a study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
• The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
• The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
• The US contributed to the largest incident population of Acute Kidney Injury, accounting for ~ 39% in the 7MM in 2022.
• Among EU4 and the UK, Germany accounted for the highest number of Acute Kidney Injury cases, followed by France, whereas Spain accounted for the lowest cases in 2022.
• The stage-specific cases of Acute Kidney Injury include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I Acute Kidney Injury followed by stage II and Stage III.
• The leading Acute Kidney Injury Companies such as Atox Bio, AM-Pharma Holding, Quark Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, Vifor Pharma, and others.
• Promising Acute Kidney Injury Therapies such as RBT-1, OCE-205 and others.

Stay ahead in the Acute Kidney Injury Therapeutics Market with DelveInsight's Strategic Report @ Acute Kidney Injury Market Outlook- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Epidemiology Segmentation in the 7MM
• Total Incident Population of Acute Kidney Injury in Hospitalized Patients
• Mortality Adjusted Incident Population of Acute Kidney Injury in Hospitalized Patients
• Stage-specific Incident Population of Acute Kidney Injury
• Age-specific Incident Population of Acute Kidney Injury

Download the report to understand which factors are driving Acute Kidney Injury Epidemiology trends @ Acute Kidney Injury Prevalence- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Emerging Drugs
• RBT-1: Renibus Therapeutics
RBT-1 by Renibus Therapeutics is an investigational drug that upregulates anti-inflammatory, antioxidant, and iron-scavenging pathways, activating a cytoprotective preconditioning response to reduce the risk of postoperative complications and improve patient outcomes following cardiothoracic surgery. The RBT-1-mediated pharmacologic preconditioning is thought to induce broad organ protection, thereby mitigating the risks of postoperative complications and improving both short- and long-term outcomes. In July 2023, Renibus Therapeutics announced that the US FDA granted Breakthrough Therapy Designation to RBT-1 for the reduction in risk of postoperative complications in patients undergoing cardiothoracic surgery and confirmed its alignment with the company's planned Phase III pivotal trial.

• OCE-205: Ocelot Bio
Ocelot Bio's lead asset, OCE-205, is a therapeutic peptide with a differentiated mechanism of action that has the potential to improve outcomes for patients with complications of end-stage liver disease (ESLD). OCE-205's innovation emanates from its design as a mixed agonist-antagonist peptide selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (v2) receptor activity at drug concentrations well above those used in treating ESLD.

Acute Kidney Injury Drugs Market Insights
Patients suffering from Acute Kidney Injury are often prescribed diuretics, with loop diuretics being the most commonly recommended class of dialectics. Furosemide, which is a potent loop diuretic, is frequently used in different stages of Acute Kidney Injury since it offers the possibility of eliminating large amounts of electrolytes and water as long as the kidneys are capable of filtration.

To know more about Acute Kidney Injury treatment guidelines, visit @ Acute Kidney Injury Treatment Market Landscape- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Companies
Atox Bio, AM-Pharma Holding, Quark Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, Vifor Pharma, and others.

Acute Kidney Injury Market Outlook
A robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the Acute Kidney Injury therapeutics market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs.

Learn more about the FDA-approved drugs for Acute Kidney Injury @ Drugs for Acute Kidney Injury Treatment- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Kidney Injury Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Acute Kidney Injury Companies- Atox Bio, AM-Pharma Holding, Quark Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, Vifor Pharma, and others.
• Acute Kidney Injury Therapies- RBT-1, OCE-205 and others.
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury Market Drivers and Barriers
• Acute Kidney Injury Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. ACUTE KIDNEY INJURY MARKET OVERVIEW AT A GLANCE
7. DISEASE BACKGROUND AND OVERVIEW
8. TREATMENT AND PREVENTION
9. GUIDELINES
10. EPIDEMIOLOGY AND PATIENT POPULATION
11. PATIENT JOURNEY
12. EMERGING DRUGS
13. Acute Kidney Injury: THE 7MM ANALYSIS
14. KOL VIEWS
15. Acute Kidney Injury UNMET NEEDS
16. SWOT ANALYSIS
17. MARKET ACCESS AND REIMBURSEMENT
18. APPENDIX
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER
21. ABOUT DELVEINSIGHT

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.